Congresses, Symposia, and Scientific Meetings

10.1 Planning Before the Meeting

The quality of congress execution is determined largely before the first session begins. Scientific meetings are too busy, too noisy, and too compressed to allow improvisation to work well. A good pre-meeting plan answers four basic questions. What matters: which data, topics, and stakeholders deserve attention. Why it matters: what scientific or strategic questions the company needs answered. Who should be engaged: which experts, investigators, and institutional voices are worth time during the meeting. How the work will be captured: what system will be used so that important observations survive the event.

The first step is to define the purpose of attending that specific meeting. Not every congress serves the same function. Some meetings are major evidence-shaping events where pivotal data or competitor updates may alter the field. Others are narrower specialty gatherings where the most important value lies in expert access and discussion quality rather than dramatic data releases. The MSL should know which type of meeting this is and plan accordingly. If the meeting is likely to reset scientific conversation, the MSL’s preparation should emphasize evidence tracking, reaction testing, and rapid synthesis. If the meeting is more relationship driven, the plan should emphasize targeted expert engagement and deeper conversation.

Session planning is the next task. Many MSLs make the mistake of building a broad schedule that looks productive but lacks prioritization. They attend too many sessions of moderate value and miss the few that will actually shape physician questions afterward. A better approach is to identify a small number of must-cover presentations and posters, a second tier of useful sessions if timing allows, and a short watch list of competitor or disease-state topics that may matter more than expected. This forces choices in advance and makes real-time adjustments easier once the meeting becomes crowded and unpredictable.

Pre-congress reading also matters. The MSL should review accepted abstracts, late-breaker announcements, company materials, previous relevant publications, and likely competitor data before arriving. The goal is not to memorize every line. The goal is to know enough that the MSL can recognize what is genuinely new, what confirms previous trends, and what is likely to trigger skepticism or enthusiasm among experts. Without that baseline, every presentation sounds important and the MSL loses the ability to separate signal from routine motion.

Expert planning deserves equal attention. The MSL should identify which external stakeholders are expected to attend, who would be strategically valuable to meet, what relationship stage each person is in, and what a successful interaction would look like. Not every meeting needs a long agenda. Sometimes the goal is simply to secure a brief but meaningful exchange after a session. In other cases, the MSL may want a more deliberate conversation over coffee or between scheduled events. The point is to avoid arriving with a passive hope of “seeing who is around.” Congress time is too expensive for that.

Internal alignment is another part of preparation that is often underdone. Before the meeting, the MSL should know what internal teams most want to learn. Medical affairs may want to understand expert reactions to a new endpoint. Clinical teams may care about investigator feedback or emerging trial design questions. Commercial partners may need to understand how competitor narratives are forming, within appropriate boundaries. A pre-meeting alignment conversation helps the MSL attend with sharper hypotheses and increases the odds that post-congress reporting will be relevant rather than generic.

Logistics matter more than they seem. Where are the priority sessions located? Which time windows are realistically available for expert meetings? How much movement across the venue is required? Which poster halls or satellite symposia are most likely to matter? An MSL does not need military-grade planning, but loose logistics create missed opportunities. A realistic schedule with travel time, fallback options, and protected note-taking blocks is usually better than an overstuffed calendar that looks ambitious but collapses under real conditions.

It is also wise to prepare a capture framework before the event begins. Decide in advance how the MSL will record scientific updates, competitive intelligence, expert reactions, and follow-up needs. A simple structure works best: session notes, key data points, anticipated physician questions, expert quotes or reactions, implications, and next actions. The more the structure is defined ahead of time, the less likely the MSL is to return with fragments that cannot be synthesized.

A short pre-congress checklist can keep planning disciplined:

• Priority science: the data presentations, posters, and disease-state topics that matter most.
• Priority people: the external experts and investigators worth targeted engagement.
• Priority questions: the hypotheses or uncertainties the MSL wants to test at the meeting.
• Priority outputs: the internal insights, summaries, and actions expected after the event.

Good preparation does not make the meeting rigid. It makes the MSL more adaptable once reality starts changing. Congresses always include surprises: a late-breaking result lands differently than expected, a competitor presentation generates stronger reaction than the company predicted, or an unexpected conversation reveals a concern that had not surfaced in the field before. The purpose of planning is not to eliminate surprise. It is to be prepared enough to recognize which surprises matter.

10.2 Engaging External Experts During the Event

Congresses and scientific meetings create rare conditions for expert engagement. Busy physicians who are difficult to access in their home institutions may be present, intellectually alert, and thinking actively about new science. At the same time, they are also overscheduled, distracted, and approached by many people. This makes meeting execution more important, not less. The MSL who uses congress time well can deepen relationships quickly. The MSL who treats the event as a networking scramble usually leaves with many brief interactions and little durable value.

The first discipline is intentionality. Every expert conversation should have a reason. That reason may be narrow, such as testing reaction to a specific data presentation. It may be broader, such as understanding how a recognized thought leader is interpreting an emerging trend in the disease area. Or it may be relationship focused, particularly with a high-priority expert whose access is otherwise limited. But the MSL should never approach the interaction as mere visibility. Visibility is not valuable.

Context matters in congress conversations. An exchange immediately after a late-breaking session is different from a planned meeting later in the day. A hallway comment after a poster presentation can be highly revealing, but it usually has to be short and sharp. A breakfast or coffee conversation allows more depth but still benefits from focus. The MSL should adapt to the setting rather than trying to force one style of exchange everywhere.

Openings matter at congresses because time is often compressed. A strong opener quickly establishes why the MSL is approaching now and what question or topic is worth the physician’s attention. “I wanted to get your reaction to the updated durability data, particularly in light of the subgroup discussion that came up in the session,” is stronger than a generic greeting followed by an unfocused prompt. Experts appreciate clarity, especially in high-traffic settings.

Listening is even more important at meetings than in routine office visits. Congress environments produce fresh, less filtered reactions. Physicians are often more candid when responding to new data they have just seen. The MSL should listen for what surprises them, what concerns them, what they dismiss, and what they think others in the field will overreact to. Those distinctions are valuable. A physician’s personal view is useful. That physician’s view of how the broader field is likely to interpret the evidence can be even more useful.

Not every conversation should be about the company’s own data. Strong MSLs at congresses engage around the science that matters to the expert, including disease-state shifts, competitor results, methodological controversies, emerging biomarkers, and unresolved clinical questions. This creates higher-quality dialogue and often yields better insight than trying to steer every discussion back to the brand. Physicians notice quickly whether the MSL is scientifically present or merely brand aware.

Congress engagement also requires discipline around boundaries. The MSL should remain clearly within scientific exchange and compliance guardrails, particularly in public settings. Discussions may happen in booths, poster halls, informal receptions, or crowded corridors. The MSL must be careful about what is discussed, how materials are handled, and whether the setting supports the level of detail being requested. Sensitive questions may need to be routed to a more appropriate follow-up rather than answered on the spot.

Another important skill is managing density. Congresses create a temptation to maximize the number of expert touches. But ten shallow conversations rarely equal three meaningful ones. The MSL should prioritize depth with the right people over sheer volume. A high-value interaction often includes one well-asked question, one important reaction, and one clear next step. That is enough if it advances understanding or relationship quality.

It helps to think of congress engagement in three categories. Planned meetings: scheduled conversations with clear objectives. Opportunistic exchanges: brief but intentional interactions triggered by sessions, posters, or chance encounters. Relationship maintenance: short check-ins that preserve continuity with important experts. Each type has value, but each should be handled differently. Problems arise when the MSL treats all three as interchangeable.

One of the highest-value behaviors during a meeting is testing interpretation rather than seeking praise. Instead of asking, “What did you think?” in a broad way, the MSL can ask, “Do you think these data change confidence in earlier-line use, or do the selection questions still dominate?” or “Was the endpoint enough for you, or do you still view the evidence as incomplete?” Questions like these surface reasoning and give the MSL something substantive to bring back internally.

Congresses are also an excellent setting to identify emerging experts. Some of the most valuable external relationships start not with a famous national KOL but with a thoughtful investigator, discussant, or institutional voice whose influence is beginning to rise. The MSL should pay attention to who asks smart questions, who others gather around after sessions, and who interprets data in a way that seems likely to spread. Those signals often matter more than who had the largest formal speaking role.

The best congress interactions usually end with a clear follow-up. The expert may want a publication, a future discussion once the full manuscript is available, or a broader conversation involving colleagues back at the institution. Or the MSL may realize that the exchange revealed an insight worth revisiting later. Congress time is rarely the endpoint. It is often the acceleration point for a relationship or a scientific thread that should continue after the meeting ends.

10.3 Capturing Competitive Intelligence and Scientific Updates

Congresses are among the richest sources of real-time scientific intelligence available to a field medical organization. They reveal not only what the data are, but how those data are being framed, challenged, discussed, and absorbed by the medical community. Yet many MSLs return from meetings with notes that are too broad to be useful: “competitor data looked strong,” “lots of excitement about biomarker use,” or “field still uncertain about safety.” That kind of reporting wastes the opportunity. Good congress capture is specific, comparative, and oriented toward what will matter in later scientific exchange.

Start with scientific updates. For every priority session, poster, or symposium, the MSL should capture the core finding, what is new relative to prior knowledge, what methodological limitations matter, and what physician questions the update is likely to generate. The goal is not to rewrite the abstract. It is to translate the scientific event into field relevance. A presentation may appear positive on the surface but raise new concerns about generalizability, monitoring burden, or sequencing. Another may not change the evidence base much at all but may strengthen confidence because the data now look more mature. These distinctions matter.

Competitive intelligence should be handled with the same discipline. The MSL should not think of competitor capture as gossip collection. It is evidence analysis. Which competitor trials were presented, and what do they actually show? Which results are likely to resonate with physicians, and why? Where are the weaknesses that experts are already noticing? What story is the competitor likely to build from the data, and which parts of that story are scientifically strong versus rhetorically convenient? The MSL’s value is in answering those questions with calm accuracy.

It is useful to capture competitive intelligence at three levels. Level one: data facts, such as endpoints, outcomes, subgroups, safety signals, design features, and stated conclusions. Level two: field interpretation, meaning what experts are saying about those data in private discussion and public Q&A. Level three: likely impact, including which physician questions or comparison pressures are likely to arise in the weeks ahead. Most weak reporting stops at level one. High-value reporting reaches level three.

Public discussion is often as informative as the presentation itself. Question-and-answer sessions, discussant remarks, session chair comments, and poster-side debates often reveal what the field sees as unresolved. The MSL should pay close attention to where the conversation becomes sharp. If multiple audience members challenge the same endpoint or repeatedly ask about the same subgroup, that is a signal. If a discussant praises the data but emphasizes one major limitation, that framing may shape how physicians talk about the study afterward. Capturing those interpretive signals is essential.

Another important habit is separating evidence from narrative. A competitor may present modest data but frame them as decisive. Or the opposite may occur: a data set with real importance may be presented in a way that fails to generate a strong reaction. The MSL should record both the evidence and the emerging narrative around it. That distinction helps internal teams prepare for what the field will actually discuss, not just what the slides showed.

In practice, a clean capture format often includes: study or session name, what is new, key strengths, key limitations, likely physician questions, expert reactions heard, and implications for our field discussions. This structure makes post-congress synthesis far easier and prevents the MSL from producing notes that are dense but unusable.

Speed matters, but so does accuracy. Congress environments tempt people to report fast impressions before thinking carefully. An MSL should resist that. The first reaction to a late-breaker may be overly enthusiastic or overly dismissive. Better to capture the initial signal clearly, then refine the interpretation once the full presentation, questions, and early expert conversations are absorbed. Being first internally is less important than being right enough to help others think.

A few capture errors are common and worth avoiding. One is confusing personal reaction with field reaction. The MSL may not find a competitor data set impressive, but if leading experts clearly do, that matters. Another is overweighting highly vocal experts and underweighting repeated moderate reactions across many credible physicians. A third is reporting only favorable implications for the company and ignoring areas where competitor data may create real scientific pressure. High-quality intelligence is honest, not comforting.

The best MSLs also use congress capture to anticipate downstream needs. If new competitor data will likely trigger comparative questions, the MSL should note that explicitly. If a new presentation raises uncertainty around a class safety issue, the MSL should identify the likely implications for field medical training. If experts repeatedly highlight the same unresolved population, that may matter for future evidence generation. In other words, capture is not complete until the MSL has translated the update into what the organization will need to do next.

10.4 Writing the Post-Congress Summary and Action Plan

A congress is only valuable to the broader organization if what was learned can be understood and acted on afterward. The post-congress summary is where the MSL proves that the meeting was more than attendance. A weak summary is a travel diary with slides. A strong summary is a decision-support document. It tells internal teams what changed, what matters, what questions are likely to surface next, and what actions are now worth taking.

The first rule is speed with structure. Post-congress reporting should happen quickly enough that the information is still timely, but not so quickly that it is just a dump of notes. A strong summary usually begins with the few most important developments from the meeting. What changed: the major scientific, competitive, or field-perception shifts. Why it matters: the likely implications for external engagement, evidence interpretation, or internal planning. This executive layer matters because many internal readers will not consume a long report line by line.

Below that high-level summary, the report should be organized into practical sections. One section might cover major scientific updates from the company’s own disease area. Another may summarize relevant competitor presentations. Another may capture expert reactions and field themes. A final section should translate all of that into recommended actions. The point is not to make the report long. The point is to make it usable by different audiences without losing coherence.

The action plan is what most post-congress documents lack. It is not enough to say that physicians are likely to ask more about a new subgroup analysis. The summary should go further: what should the organization do about that? Perhaps field medical materials need refinement. Perhaps internal training needs to prepare MSLs for a new challenge question. Perhaps a medical director should explore the issue in an upcoming advisory board. Perhaps clinical teams should note a repeated unmet need that surfaced more strongly at this meeting than before. The MSL is not required to make the final decision, but the MSL should frame the decision space clearly.

A useful post-congress action framework includes four parts. Theme: the key scientific or strategic issue. Evidence: what from the congress supports the conclusion, including data and expert reaction. Implication: why this matters for the business or the medical plan. Action: what should be considered next and by whom. This keeps the document from becoming descriptive only.

The summary should also separate fact from interpretation. If a competitor presented a certain hazard ratio, that is a fact. If leading experts at the meeting viewed the result as more practice relevant than expected, that is field interpretation. If the MSL believes this will increase comparative pressure in community accounts, that is an informed projection. All three are useful, but they should not be blended carelessly. Clear separation improves internal trust.

Audience tailoring matters. A medical affairs leader may want a crisp synthesis of evidence implications and expert themes. A clinical development colleague may care more about how investigators reacted to endpoint design or patient population selection. A market access partner may want to understand how pathway-relevant evidence is evolving. Commercial teams may need a clear, guardrail-respecting view of what scientific questions are likely to arise. One master summary can support all of these audiences, but the MSL should know which parts are likely to matter most to each.

A concise template can help:

• Top takeaways: the three to five most important meeting developments.
• Scientific updates: what new data matter and why.
• Competitive implications: what competitor evidence and narratives are likely to affect the field.
• Expert reactions: the most important themes heard from external stakeholders.
• Recommended actions: training, materials, evidence planning, follow-up meetings, or issues to monitor.

Good post-congress writing is specific. “High interest in biomarker implementation” is weak. “Multiple academic and community experts questioned whether current testing workflow can support earlier-line patient identification at scale” is much better. Specificity allows action. Vague enthusiasm does not.

The best post-congress reports also close the loop to territory work. Which experts deserve follow-up now? Which accounts are likely to need scientific discussion soon? Which new data require the MSL to adjust territory priorities or meeting objectives? Congresses should not sit apart from routine field work. They should immediately reshape how the MSL approaches the next wave of interactions.

The final standard is simple. After reading the post-congress summary, an internal stakeholder should understand what happened, what changed, what the field seems to think, and what the company should consider doing next. If the report achieves that, the MSL has converted the meeting into organizational value. If not, the meeting was mostly motionless. Congresses reward preparation, disciplined engagement, sharp capture, and structured follow-through. Done well, they are among the highest-yield activities in the medical field.